Next Article in Journal
Impact of Particle Size and Polydispersity Index on the Clinical Applications of Lipidic Nanocarrier Systems
Previous Article in Journal
Sustained Release Drug Delivery Applications of Polyurethanes
Article Menu

Export Article

Open AccessArticle
Pharmaceutics 2018, 10(2), 56; https://doi.org/10.3390/pharmaceutics10020056

Combining MucilAir™ and Vitrocell® Powder Chamber for the In Vitro Evaluation of Nasal Ointments in the Context of Aerosolized Pollen

1
Department of Drug Delivery, PharmBioTec GmbH, 66123 Saarbrücken, Germany
2
Department of Biopharmaceutics and Pharmaceutical Technology, Department of Pharmacy, Saarland University, 66123 Saarbrücken, Germany
3
Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), Helmholtz Center for Infection Research (HZI), 66123 Saarbrücken, Germany
4
Department of Scientific Affairs Consumer Health, Bayer Vital GmbH, 51368 Leverkusen, Germany
5
Bock Project Management, 54456 Tawern, Germany
*
Author to whom correspondence should be addressed.
Received: 30 March 2018 / Revised: 27 April 2018 / Accepted: 27 April 2018 / Published: 10 May 2018
View Full-Text   |   Download PDF [9293 KB, uploaded 10 May 2018]   |  

Abstract

Hay fever is notoriously triggered when nasal mucosa is exposed to allergenic pollen. One possibility to overcome this pollen exposure may be the application of an ointment with physical protective effects. In this context, we have investigated Bepanthen® Eye and Nose Ointment and the ointment basis petrolatum as reference while using contemporary in vitro techniques. Pollen from false ragweed (Iva xanthiifolia) was used as an allergy-causing model deposited as aerosol using the Vitrocell® Powder Chamber (VPC) on Transwell® inserts, while being coated with either Bepanthen® Eye and Nose Ointment and petrolatum. No pollen penetration into ointments was observed upon confocal scanning laser microscopy during an incubation period of 2 h at 37 °C. The cellular response was further investigated by integrating the MucilAir™ cell system in the VPC and by applying pollen to Bepanthen® Eye and Nose Ointment covered cell cultures. For comparison, MucilAir™ were stimulated by lipopolysaccharides (LPS). No increased cytokine release of IL-6, TNF-α, or IL-8 was found after 4 h of pollen exposure, which demonstrates the safety of such ointments. Since nasal ointments act as a physical barrier against pollen, such preparations might support the prevention and management of hay fever. View Full-Text
Keywords: allergy prevention; pollen; aerosol deposition in vitro system; nasal mucosa; Bepanthen® Eye and Nose Ointment allergy prevention; pollen; aerosol deposition in vitro system; nasal mucosa; Bepanthen® Eye and Nose Ointment
Figures

Graphical abstract

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Metz, J.; Knoth, K.; Groß, H.; Lehr, C.-M.; Stäbler, C.; Bock, U.; Hittinger, M. Combining MucilAir™ and Vitrocell® Powder Chamber for the In Vitro Evaluation of Nasal Ointments in the Context of Aerosolized Pollen. Pharmaceutics 2018, 10, 56.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Pharmaceutics EISSN 1999-4923 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top